Management of Invasive Fungal Sinusitis

  • Rajeev Soman
  • Ayesha Sunavala


Fungi have long been implicated as important pathogens in selected patients with acute or chronic sinusitis. Inhalation of fungal spores is considered to be the primary means by which these organisms gain access to the sinonasal tract. Fungal sinusitis is an important clinical entity. However, changing terminology and emerging theories of pathogenesis make it an area of confusion and controversy. An analysis of tissue invasion and host immunological response is an important step in the evaluation of the patient.


Antifungal Agent Invasive Aspergillosis Invasive Fungal Infection Haematopoietic Stem Cell Transplant Lipid Formulation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Demuri GP, Wald ER. Sinusitis. In: Mandell GL, Benett JE, Dolin R, editors. Principles and practice of infectious diseases, vol. 2. 7th ed. Philadelphia: Elsevier Churchill Livingstone; 2010. p. 842.Google Scholar
  2. 2.
    Kontoyiannis DP, Lewis RE. How I treat mucormycosis. Blood. 2011;118(5):1216–24.PubMedCrossRefGoogle Scholar
  3. 3.
    Kontoyiannis DP, Lewis RE. Agents of mucormycosis and entomophthoromycosis. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases, vol. 2. 7th ed. Philadelphia: Elsevier Churchill Livingstone; 2010. p. 3257–67.Google Scholar
  4. 4.
    Spellberg B, Edwards Jr J, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev. 2005;18:556–69.PubMedCrossRefGoogle Scholar
  5. 5.
    Sun HY, Singh N. Mucormycosis: its contemporary face and management strategies. Lancet Infect Dis. 2011;11(4):301–11.PubMedCrossRefGoogle Scholar
  6. 6.
    Ben-Ami R, Lewis RE, Kontoyiannis DP. Immunocompromised hosts: immunopharmacology of modern antifungals. Clin Infect Dis. 2008;47:226–35.PubMedCrossRefGoogle Scholar
  7. 7.
    Spellberg B, Ibrahim AS, et al. Mucormycosis. In: Longo DL, editor. Harrison’s principles of internal medicine. 18th ed. London: The McGraw-Hill Companies, Inc.; 2012. p. 1663–6.Google Scholar
  8. 8.
    Thompson 3rd GR, Wiederhold NP. Isavuconazole: a comprehensive review of spectrum of activity of a new triazole. Mycopathologia. 2010;170:291–313.PubMedCrossRefGoogle Scholar
  9. 9.
    John BV, Chamilos G, Kontoyiannis DP. Hyperbaric oxygen as an adjunctive treatment for zygomycosis. Clin Microbiol Infect. 2005;11(7):515–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Kaide CG, Khandelwal S. Hyperbaric oxygen: applications in infectious disease. Emerg Med Clin North Am. 2008;26(2):571–95.PubMedCrossRefGoogle Scholar
  11. 11.
    Neuman TS, Thom SR, editors. Physiology and rationale of hyperbaric oxygen therapy. Philadelphia: Saunders Elsevier; 2008. pp 321–47.Google Scholar
  12. 12.
    Soman R, Gupta N, Shetty A, Rodrigues C. Deferasirox in mucormycosis: hopefully, not defeated. J Antimicrob Chemother. 2012;67(3):783–4.PubMedCrossRefGoogle Scholar
  13. 13.
    Ben-Ami R, Lewis RE, Tarrand J, Leventakos K, Kontoyiannis DP. Antifungal activity of colistin against mucorales species in vitro and in a murine model of Rhizopus oryzae pulmonary infection. Antimicrob Agents Chemother. 2010;54:484–90.PubMedCrossRefGoogle Scholar
  14. 14.
    Terblanche M, Almog Y, Rosenson RS, Smith TS, Hackam DG. Statins and sepsis: multiple modifications at multiple levels. Lancet Infect Dis. 2007; 7:358–68.PubMedCrossRefGoogle Scholar
  15. 15.
    Ashdown B, Tien R, Felsberg G. Aspergillosis of the brain and paranasal sinuses in immunocompromised patients: CT and MR imaging findings. AJR Am J Roentgenol. 1994;162:155–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Patterson TF. Aspergillus species. In: Mandell GL, Benett JE, Dolin R, editors. Principles and practice of infectious diseases, vol. 2. 7th ed. Philadelphia: Elsevier Churchill Livingstone; 2010. p. 3241–55.Google Scholar
  17. 17.
    Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the infectious diseases society of America. Clin Infect Dis. 2008;46:327–60.PubMedCrossRefGoogle Scholar
  18. 18.
    Chaudhary AS, Kochhar R, Kohli KK. Genetic polymorphism of CYP2C19 & therapeutic response to proton pump inhibitors. Indian J Med Res. 2008;127:521–30.Google Scholar
  19. 19.
    Cox GM, Perfect JR. Fungal rhinosinusitis. [homepage on the Internet]. 2012 [cited 25 Feb 2013]. Available from:
  20. 20.
    De Carpentier JE, Ramamurthy L, Denning DW, Taylor PH. An algorithmic approach to aspergillus sinusitis. J Laryngol Otol. 1994;108:314–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Zaas A. Fusarium, Scedosporium [homepage on the internet]. 2012 [cited 25 Feb 2013]. Available from:
  22. 22.
    Chamilos G, Macapinlac HA, Kontoyiannis DP. The use of 18F-fluorodeoxyglucose positron emission tomography for the diagnosis and management of invasive mold infections. Med Mycol. 2008;46(1):23–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Moussett S, Hermann S, Klein SA, et al. Prophylactic and interventional granulocyte transfusions in patients with haematological malignancies and life-threatening infections during neutropenia. Ann Hematol. 2005;84(11):734–41.CrossRefGoogle Scholar
  24. 24.
    Herbrecht R, Letscher-Bru V, Bowden RA, et al. Treatment of 21 cases of invasive mucormycosis with amphotericin B colloidal dispersion. Eur J Clin Microbiol Infect Dis. 2001;20:460–6.PubMedGoogle Scholar
  25. 25.
    Chamilos G, Lewis RE, Kontoyiannis DP. Delaying Amphotericin B- based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis. 2008;47(4):503–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Pagano L, Akova M, Dimopoulos G, et al. Risk assessment and prognostic factors for mold related diseases in immunocompromised patients. J Antimicrob Chemother. 2011;66(1):i5–14.PubMedCrossRefGoogle Scholar
  27. 27.
    Gomes MZ, Lewis RE, Kontoyiannis DP. Mucormycosis caused by unusual mucormycetes, non-rhizopus, mucor and lichtheimia species. Clin Microbiol Rev. 2011;24(2):411–45.PubMedCrossRefGoogle Scholar

Copyright information

© Springer India 2014

Authors and Affiliations

  1. 1.Department of Internal Medicine and Infectious DiseasesPD Hinduja HospitalMahim, MumbaiIndia

Personalised recommendations